Lenz Therapeutics Inc. announced VIZZ (aceclidine ophthalmic solution) 1.44%, a US Food and Drug Administration (FDA)-approved aceclidine-based eye drop for the treatment of presbyopia in adults, is now available. Professional product sample distribution by the sales force to optometrists and ophthalmologists has been initiated nationwide. Commercial product shipments will be initiated to consumers in October through its ePharmacy partner and are anticipated to be broadly available, including via retail pharmacies, by mid-Q4 2025.